Trevi Therapeutics Inc. (TRVI)
NASDAQ: TRVI
· Real-Time Price · USD
6.92
0.01 (0.14%)
At close: May 01, 2025, 3:59 PM
6.87
-0.79%
After-hours: May 01, 2025, 05:21 PM EDT
0.14% (1D)
| Bid | 6.8 |
| Market Cap | 669.52M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -47.91M |
| EPS (ttm) | -0.47 |
| PE Ratio (ttm) | -14.73 |
| Forward PE | -11.33 |
| Analyst | Buy |
| Ask | 7.17 |
| Volume | 1,546,678 |
| Avg. Volume (20D) | 2,313,632 |
| Open | 6.87 |
| Previous Close | 6.91 |
| Day's Range | 6.74 - 7.16 |
| 52-Week Range | 2.30 - 7.39 |
| Beta | 0.41 |
About TRVI
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo P...
Industry Biotechnology
Sector Healthcare
IPO Date May 7, 2019
Employees 26
Stock Exchange NASDAQ
Ticker Symbol TRVI
Analyst Forecast
According to 9 analyst ratings, the average rating for TRVI stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 188.81% from the latest price.
Stock Forecasts1 month ago
+41.16%
Trevi Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
4 months ago
+15.83%
Trevi Therapeutics shares are trading higher after HC Wainwright & Co. reiterated a Buy rating on the stock and raised its price target from $6 to $7.5.
